0000849146-16-000218.txt : 20161216 0000849146-16-000218.hdr.sgml : 20161216 20161216143221 ACCESSION NUMBER: 0000849146-16-000218 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20161216 ITEM INFORMATION: Other Events FILED AS OF DATE: 20161216 DATE AS OF CHANGE: 20161216 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lifevantage Corp CENTRAL INDEX KEY: 0000849146 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 841097796 STATE OF INCORPORATION: CO FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35647 FILM NUMBER: 162056004 BUSINESS ADDRESS: STREET 1: 9785 S. MONROE STREET STREET 2: SUITE 300 CITY: SANDY STATE: UT ZIP: 84070 BUSINESS PHONE: 801-432-9000 MAIL ADDRESS: STREET 1: 9785 S. MONROE STREET STREET 2: SUITE 300 CITY: SANDY STATE: UT ZIP: 84070 FORMER COMPANY: FORMER CONFORMED NAME: LIFELINE THERAPEUTICS, INC. DATE OF NAME CHANGE: 20041019 FORMER COMPANY: FORMER CONFORMED NAME: YAAK RIVER RESOURCES INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: ANDRAPLEX CORP DATE OF NAME CHANGE: 19920406 8-K 1 lfvn-8xkrevisedfy2017annua.htm 8-K Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 ______________________________

 FORM 8-K
 ______________________________ 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 16, 2016
 ______________________________
 
 
 
 
 
 
LIFEVANTAGE CORPORATION
(Exact name of registrant as specified in its charter)
______________________________ 
 
 
 
 
 
 
Colorado
 
001-35647
 
90-0224471
(State or other Jurisdiction of Incorporation)
 
(Commission File Number)
 
(IRS Employer Identification No.)
 
 
9785 S. Monroe Street, Suite 300, Sandy, UT 84070
(Address of Principal Executive Offices and Zip Code)
 
 
 
 
 
Registrant’s telephone number, including area code: (801) 432-9000
______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
 
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 





Item 8.01    Other Events.
LifeVantage Corporation (the “Company”, “we”, “our” or “us”) previously scheduled its fiscal year 2017 Annual Meeting of Shareholders for February 22, 2017 (the “FY 2017 Annual Meeting”) as publicly disclosed on December 14, 2016 on the Company’s Current Report on Form 8-K. The Company has rescheduled the FY 2017 Annual Meeting for February 16, 2017. In our proxy statement relating to our fiscal year 2016 annual meeting of shareholders (the “FY 2016 Annual Meeting”), we disclosed the deadlines by which shareholders must notify us of any proposals to be included in the proxy materials distributed by us for the FY 2017 Annual Meeting.
Because the expected date of the FY 2017 Annual Meeting has been established for February 16, 2017, which is more than 30 days from the anniversary of our FY 2016 Annual Meeting, we have set a new deadline for the receipt of shareholder proposals submitted in accordance with Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), for inclusion in our proxy materials for the FY 2017 Annual Meeting. In order to be considered timely, such proposals must be received by our Corporate Secretary no later than December 27, 2016, which is a reasonable time before we begin to print and mail our proxy materials. Proposals must be sent to the Company’s principal executive office c/o Corporate Secretary, 9785 S. Monroe Street, Suite 300, Sandy, Utah 84070, and must also comply with Rule 14a-8 of the Exchange Act regarding the inclusion of shareholder proposals in company-sponsored proxy materials.
Shareholders also have the right under our bylaws to directly nominate director candidates and make other shareholder proposals by following specified procedures. For a shareholder proposal for the FY 2017 Annual Meeting that is not intended to be included in our proxy statement under Rule 14a-8, including director nominations, the shareholder must (1) provide the information required by our bylaws and (2) give timely notice to our Corporate Secretary at the address above in accordance with our bylaws, which, in general, require that the notice be received by our Corporate Secretary by no later than December 27, 2016, which is the tenth day following the date on which public announcement of the date of the annual meeting is first made.




SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
Date: December 16, 2016
LIFEVANTAGE CORPORATION
  
By: /s/ Beatryx Washington   
Name: Beatryx Washington
Title: Senior Vice President, Legal Affairs